NCT02489318 · MORE INFO

Limitations, agreements, and source contact

A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC · Source last updated 2026-08-31

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

other Details: If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation.
pi Sponsor Employee: false
restriction Type: OTHER
restrictive Agreement: true

point Of Contact

email: ClinicalTrialDisclosure@its.jnj.com
organization: Aragon Pharmaceuticals, Inc.
phone: 844-434-4210
title: Executive Medical Director

Complete source fields

certain Agreement

other Details: If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation.
pi Sponsor Employee: false
restriction Type: OTHER
restrictive Agreement: true

point Of Contact

email: ClinicalTrialDisclosure@its.jnj.com
organization: Aragon Pharmaceuticals, Inc.
phone: 844-434-4210
title: Executive Medical Director

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice